Artbio AS is a company that specializes in research and product development within cancer treatment. The company is developing a new class of alpha radioligand therapies, with a patient-centered approach that emphasizes both efficacy and safety. Artbio AS has an extensive portfolio with over ten pipeline programs, including the leading program AB001.
The company is based on a holistic approach, which is rooted in a deep understanding of cancer biology. Artbio AS has a strong scientific heritage from the University of Oslo and Radiumhospitalet, and has accumulated almost 100 years of experience in innovation within radioligand therapy. The therapies developed by the company have high affinity and selectivity, which helps to spare healthy tissue during treatment.